

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	2
INTENDED AUDIENCE.....	2
SCOPE OF REPORT.....	3
METHODOLOGY.....	3
INFORMATION SOURCES.....	4
AUTHOR’S CREDENTIALS.....	4
RELATED BCC WORK CREDENTIALS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER.....	5
CHAPTER TWO: SUMMARY.....	6
SUMMARY.....	6
<i>SUMMARY TABLE THE WORLDWIDE MARKET FOR</i>	
<i>ANTIPSYCHOTIC DRUGS, THROUGH 2014 (\$, MILLIONS).....</i>	7
<i>SUMMARY FIGURE THE WORLDWIDE MARKET FOR</i>	
<i>ANTIPSYCHOTIC DRUGS, 2010–2014 (\$, MILLIONS).....</i>	7
CHAPTER THREE: OVERVIEW.....	8
DEFINITION OF AN ANTIPSYCHOTIC DRUG.....	8
HISTORY OF ANTIPSYCHOTIC DRUGS.....	9
TYPES OF ANTIPSYCHOTICS ON THE MARKET.....	10
TYPICAL ANTIPSYCHOTICS.....	10
Typical Antipsychotics (Continued).....	11
<i>TABLE 1 CLASSES OF TYPICAL ANTIPSYCHOTICS ON THE</i>	
<i>MARKET AND THEIR SIDE EFFECTS.....</i>	12
ATYPICAL ANTIPSYCHOTICS.....	13
<i>TABLE 2 CURRENTLY APPROVED ATYPICAL ANTIPSYCHOTICS ON</i>	
<i>THE MARKET.....</i>	14
<i>TABLE 2 (CONTINUED).....</i>	15
<i>TABLE 3 FEATURES OF TYPICAL VERSUS ATYPICAL</i>	
<i>ANTIPSYCHOTICS.....</i>	15
<i>TABLE 4 COST OF SELECTED ATYPICAL AND TYPICAL</i>	
<i>ANTIPSYCHOTIC DRUGS (\$).....</i>	16
RECEPTOR TARGETS OF ANTIPSYCHOTIC DRUGS.....	16
DOPAMINE.....	17
SEROTONIN.....	18
GLUTAMATE.....	18
TACHYKININ.....	19
GLUCOCORTICOID.....	20
SIDE EFFECTS OF ANTIPSYCHOTICS.....	20
NEUROLOGIC SIDE EFFECTS (EXTRAPYRAMIDAL	
SYMPTOMS).....	21
ANTICHOLINERGIC SIDE EFFECTS.....	22

CARDIOVASCULAR SIDE EFFECTS	22
METABOLIC SIDE EFFECTS.....	23
OTHER SIDE EFFECTS	24
<i>TABLE 5 COMPARISON OF SIDE EFFECT PROFILES OF ANTIPSYCHOTICS ON THE MARKET.....</i>	<i>25</i>
ANTIPSYCHOTICS IN CLINICAL DEVELOPMENT.....	25
<i>TABLE 6 ANTIPSYCHOTICS IN CLINICAL TRIALS, ORDERED BY PHASE.....</i>	<i>26</i>
<i>TABLE 6 (CONTINUED).....</i>	<i>27</i>
<i>TABLE 7 NUMBER OF ANTIPSYCHOTICS IN CLINICAL TRIALS, BY PHASE (NUMBER / %).....</i>	<i>27</i>
<i>FIGURE 1 ANTIPSYCHOTICS IN CLINICAL TRIALS BY PRIMARY RECEPTOR TARGET</i>	<i>28</i>
<i>TABLE 8 COMPANIES WITH MORE THAN ONE ANTIPSYCHOTICS IN CLINICAL TRIALS OR ON THE MARKET*</i>	<i>29</i>
CHAPTER FOUR: TECHNOLOGY OVERVIEW	30
TECHNOLOGY OVERVIEW	30
<i>TABLE 9 SALES OF ATYPICAL ANTIPSYCHOTICS BY FORMULATION, THROUGH 2014 (\$, MILLIONS).....</i>	<i>31</i>
<i>TABLE 10 ADMINISTRATION PROFILES OF LONG-ACTING ATYPICAL ANTIPSYCHOTICS.....</i>	<i>31</i>
CHAPTER FIVE: PATENT EVALUATION.....	32
PATENT LENGTHS AND MARKET EXCLUSIVITY.....	32
<i>TABLE 11 PATENT EXPIRATION DATES FOR ANTIPSYCHOTICS ON THE MARKET OR IN PHASE III DEVELOPMENT.....</i>	<i>33</i>
<i>TABLE 12 SALES OF ANTIPSYCHOTICS POTENTIALLY FACING GENERIC COMPETITION BY THE END OF 2014 (\$ MILLIONS).....</i>	<i>34</i>
CHAPTER SIX: ANTIPSYCHOTICS ON THE MARKET AND IN DEVELOPMENT	35
<i>TABLE 13 GLOBAL MARKET FOR ANTIPSYCHOTICS BY INDIVIDUAL DRUG, THROUGH 2014 (\$ MILLIONS).....</i>	<i>35</i>
<i>TABLE 13 (CONTINUED).....</i>	<i>36</i>
<i>TABLE 14 GLOBAL MARKET FOR ANTIPSYCHOTIC DRUGS BY MECHANISM OF ACTION, THROUGH 2014 (\$ MILLIONS).....</i>	<i>37</i>
DOPAMINERGIC ANTIPSYCHOTICS IN DEVELOPMENT	37
DOPAMINE D2/SEROTONIN 5-HT2A RECEPTOR ANTAGONISTS	37
<i>TABLE 15 MARKET FOR D2/5-HT2A ANTAGONISTS BY REGION, THROUGH 2014 (\$ MILLIONS).....</i>	<i>38</i>
Serdolect (Sertindole)	38
Serdolect ... (Continued).....	39
Solian (Amisulpride).....	40

Lonasen (Blonanserin)	40
Lullan (Perospirone).....	41
Saphris/Sycrest (Asenapine, ORG 5222, SCH 900274).....	41
Saphris/Sycrest (Continued).....	42
Risperdal (Risperidone).....	43
Risperdal Consta (Risperidone)	44
Risperdal Consta... (Continued)	45
Clozaril/Leponex (Clozapine)	46
Seroquel IR and XR (Quetiapine)	47
Seroquel IR and XR...(Continued)	48
Zyprexa (Olanzapine)	49
Zyprexa...(Continued).....	50
Zyprexa Relprevv/Zypadhera (Olanzapine Pamoate)	51
Fanapt (Iloperidone).....	51
Fanapt...(Continued).....	52
Iloperidone Depot	53
AZ-004 (Staccato Loxapine)	53
<i>TABLE 16 PROFILE OF AZ-004 VERSUS OTHER ANTIPSYCHOTICS</i>	
<i>FOR TREATING AGITATION</i>	54
<i>TABLE 17 AZ-004/STACCATO LOXAPINE STUDIES</i>	55
Lurasidone (SM-13496).....	56
<i>TABLE 18 LURASIDONE STUDY RESULTS</i>	57
Geodon/Zeldox (Ziprasidone).....	58
Invega (Paliperidone)	59
<i>TABLE 19 INVEGA COMPARED TO RISPERDAL</i>	60
Invega Sustenna (Paliperidone Palmitate)	60
TGOF02N.....	61
Zicronapine (Lu 31-130)	61
ATI-9242	62
YKP1447	63
DOPAMINE D2 RECEPTOR PARTIAL AGONISTS	63
<i>TABLE 20 MARKET FOR D2 PARTIAL AGONISTS BY REGION,</i>	
<i>THROUGH 2014 (\$ MILLIONS)</i>	64
Abilify (Aripiprazole, OPC-14597)	65
Aripiprazole Depot.....	66
Cariprazine (RGH-188, MP-214)	67
Cariprazine...(Continued)	68
OPC-34712	69
ACR343	70
PNB02	70
ALKS 9070 (Long-acting Aripiprazole)	71
Bifeprunox (DU-127,090)	71
SEROTONERGIC ANTIPSYCHOTICS IN DEVELOPMENT	72

<i>TABLE 21 SELECTED SEROTONIN RECEPTOR SUBTYPES AND ANTIPSYCHOTIC DRUGS BINDING TO THESE SITES</i>	73
Pimavanserin (ACP-103).....	74
Pimavanserin...(Continued).....	75
<i>TABLE 22 PIMAVANSERIN PHASE II ADJUNCTIVE SCHIZOPHRENIA EFFICACY RESULTS</i>	76
CYR-101 (MT-210).....	77
5-HT6 RECEPTOR AGONISTS AND ANTAGONISTS.....	77
AVN-211.....	77
PF-5212365 (SAM-531)	78
Eplivanserin (SR46349B).....	78
GLUTAMATERGIC ANTIPSYCHOTICS IN DEVELOPMENT.....	79
LY2140023	79
LY2140023 (Continued).....	80
ADX71149	81
AZD8529	81
AZD8418	81
Glutamatergic Modulators in Preclinical Testing.....	82
GLYCINE TRANSPORT INHIBITORS.....	82
SCH 900435 (Org 25935).....	82
RG1678.....	83
GSK1018921	83
OTHER ANTIPSYCHOTICS IN DEVELOPMENT.....	84
BL-1020.....	85
GSK1144814	86
Talnetant (SB-223412)	87
Osanetant (SR-142801)	87
Lu AA39959	88
Licarbazepine (LIC477D)	88
Corlux (Mifepristone, RU-486, C-1073).....	89
Corlux ...(Continued).....	90
SCH 900636 (ORG 34517).....	91
PDE10 Inhibitors.....	92
CHAPTER SEVEN: DISEASE APPLICATIONS.....	93
SCHIZOPHRENIA.....	93
OVERVIEW	93
SYMPTOMS OF SCHIZOPHRENIA.....	94
TREATMENT OF SCHIZOPHRENIA	95
Treatment of Schizophrenia (Continued)	96
TESTS OF SCHIZOPHRENIA DRUG EFFECTIVENESS	97
Positive and Negative Syndrome Scale (PANSS).....	97
Brief Psychiatric Rating Scale (BPRS)	97
Clinical Global Impression scale (CGI).....	97

Scale for the Assessment of Positive Symptoms/Negative Symptoms (SAPS/SANS)	98
CATIE	98
CATIE Phase 1 Results	99
<i>TABLE 23 CATIE PHASE 1 ALL-CAUSE STUDY</i>	
DISCONTINUATIONS	99
CATIE Phase 2 Results	100
CATIE Phase 3 Results	100
CUtLASS.....	101
<i>The Lancet</i> Second-generation vs First-Generation Antipsychotics Meta-analysis	102
BIPOLAR DISORDER.....	103
OVERVIEW	103
Young Mania Rating Scale.....	104
Montgomery-Asberg Depression Rating Scale	104
Hamilton Depression Rating Scale.....	104
MAJOR STUDIES USING ANTIPSYCHOTICS IN BIPOLAR DISORDER.....	105
STEP-BD.....	105
MARKET OPPORTUNITY	106
<i>TABLE 24 LIST OF APPROVED BIPOLAR I DISORDER USES FOR</i> <i>ATYPICAL ANTIPSYCHOTICS</i>	107
MAJOR DEPRESSIVE DISORDER	108
MARKET OPPORTUNITY	109
OTHER ON- AND OFF-LABEL USES OF ANTIPSYCHOTICS	110
ANXIETY SPECTRUM DISORDERS.....	110
ALZHEIMER'S AND PARKINSON'S DISEASES	111
MARKET OPPORTUNITY	111
Market Opportunity (Continued).....	112
CHAPTER EIGHT: MAJOR COMPANIES AND MARKET SHARE	113
MARKET SHARE	113
<i>TABLE 25 FORECASTED SALES AND MARKET SHARE OF</i> <i>COMPANIES WITH ANTIPYSCHOTICS ON THE MARKET, 2014 (\$</i> <i>MILLIONS/%)</i>	113
COMPANY PROFILES	114
ACADIA PHARMACEUTICALS	114
ADDEX PHARMACEUTICALS	115
ALEXZA PHARMACEUTICALS.....	116
ALKERMES.....	117
ASTRAZENECA.....	117
AstraZeneca – U.S. Headquarters	118
BIOLINERX	118
BIOTIE THERAPIES.....	119
BIOVAIL.....	119

BRISTOL-MYERS SQUIBB	120
CYRENAIC PHARMACEUTICALS.....	121
DAINIPPON SUMITOMO PHARMA	122
ELI LILLY	123
FABRE-KRAMER PHARMACEUTICALS	123
GEDEON RICHTER	124
GLAXOSMITHKLINE	125
JOHNSON AND JOHNSON	125
LIPOCINE	126
LUNDBECK	127
MITSUBISHI TANABE PHARMA.....	127
MERCK & CO.....	128
NEUROSEARCH	129
NOVARTIS	129
NPS PHARMACEUTICALS	130
OMEROS	131
OTSUKA PHARMACEUTICAL CO.....	132
PFIZER	132
Pfizer (Continued).....	133
SK GROUP	134
TITAN PHARMACEUTICALS.....	134
VANDA PHARMACEUTICALS	135

CHAPTER NINE: INTERNATIONAL ASPECTS AND REGULATORY

ISSUES	136
MARKET BY REGION	136
<i>TABLE 26 GLOBAL FORECAST FOR ANTIPSYCHOTICS MARKET BY</i>	
<i>REGION, THROUGH 2014 (\$ MILLIONS)</i>	136
MARKET BY REGION (CONTINUED).....	137
UNITED STATES	138
The FDA Modernization Act of 1997	138
Fast-track Status.....	139
Special Protocol Assessments	140
New Surveillance and Safety Requirements.....	140
Approvable Letters	140
Consumer Confidence.....	141
Medicare.....	141
Other Health Care Changes.....	142
EUROPEAN UNION	142
New Drug Approvals and Innovation	142
Drug Reimbursement and Reference Pricing.....	143
Relocation of R&D	144
JAPAN	145
New Drug Approvals	145
Regulatory Climate.....	145

Relationship Between Academia and Industry	146
CHAPTER TEN: FUTURE DIRECTIONS.....	147
THE ROLE OF BIOMARKERS AND PHARMACOGENOMICS.....	147
COMBINATION THERAPIES.....	147
THE EFFECT OF GENERIC ANTIPSYCHOTICS ON PRICE	148
THE EFFECT OF GENERIC ...(CONTINUED)	149